647-P: Efficacy and Safety of GLP-1RAs with or without Baseline SGLT2i: Post-hoc Analysis of the SUSTAIN 10 Trial

Glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter-2 inhibitor (SGLT-2i) combination data are limited. The SUSTAIN 10 trial analyzed the efficacy and safety of the GLP-1RAs semaglutide 1.0 mg and liraglutide 1.2 mg in subjects with type 2 diabetes. This post hoc analysis of SUSTAIN 10 examined clinical outcomes with these GLP-1RAs in subjects on background SGLT-2i and in those not receiving an SGLT-2i. In this post hoc analysis, SUSTAIN 10 data were stratified by SGLT-2i use at screening. ‘On-treatment without rescue medication’ and ‘on-treatment’ data were used to assess efficacy (HbA1c, body weight [BW] and systolic blood pressure [SBP]) and safety (discontinuation due to adverse events [AEs]) outcomes, respectively. Within each SGLT-2i subgroup, baseline characteristics and background medications (metformin and/or sulfonylureas) were similar between treatment arms. Reductions from baseline to week 30 in HbA1c, BW and SBP were observed with semaglutide 1.0 mg and liraglutide 1.2 mg regardless of SGLT-2i use (Figure). There were no unexpected safety concerns in subjects receiving GLP-1RA and SGLT-2i, and discontinuations due to AEs remained relatively low in both SGLT-2i subgroups.In conclusion, the results suggest that addition of a GLP-1RA to SGLT-2i treatment was associated with further reductions in HbA1c, BW and SBP without additional safety concerns.View largeDownload slideView largeDownload slide DisclosureM. Capehorn: Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc., McDonalds, Novo Nordisk, Consultant; Self; Lighterlife, Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Lilly Diabetes, Novo Nordisk, Speaker’s Bureau; Self; Novo Nordisk. A. Catarig: Employee; Self; Novo Nordisk. O. Frenkel: Employee; Self; Novo Nordisk A/S, Stock/Shareholder; Self; Novo Nordisk A/S, Thermo Fisher Scientific. C. Hindsberger: Consultant; Self; Novo Nordisk A/S, Stock/Shareholder; Self; Novo Nordisk A/S, Stock/Shareholder; Spouse/Partner; Novo Nordisk A/S. M. Marre: Board Member; Self; Merck Sharp & Dohme Corp., Consultant; Self; Novo Nordisk. H. Price: Other Relationship; Self; Napp Pharmaceuticals, Research Support; Self; Novo Nordisk, Speaker’s Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Napp Pharmaceuticals, Novo Nordisk. R. E. Pratley: Other Relationship; Self; Hanmi Pharmaceutical, Merck Sharp & Dohme Corp., Metavention, Monster Energy Company, Inc., Novo Nordisk, Pfizer Inc., Poxel SA, Sanofi, Scohia Pharma Inc., Sun Pharmaceutical Industries Ltd.